An interventional study of Functional near-infrared spectroscopy (fNIRS) and V1 stimulation electrodes in Mild Traumatic Brain Injury and Post Concussion Syndrome, sponsored by University of Wisconsin, Madison. Recruiting at 1 site in United States. Open to participants aged 20 Years to 85 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-11-04.
Sponsored by University of Wisconsin, Madison · Not applicable, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 77 studies in Post-Concussion Syndrome with a site in United States — 15 open to participants now, 20 under way, 1 of them phase 3. Post-Concussion Syndrome · United States.
Among the 77 studies in Post-Concussion Syndrome with a site in United States, this one is the 25th largest by planned enrollment of the 61 interventional ones that give a count, is one of 3 that started in 2025, is one of 35 with no phase, reaches primary completion later than 8 of the 19 other live ones, and was the 67th registered.
140 studies on the registry are indexed under Post-Concussion Syndrome; 33 are open to participants now.
Browse Post-Concussion Syndrome studies →15 of the 77 studies in Post-Concussion Syndrome with a site in United States are open now. Recruiting first, the newest first:
Summit Hyperbarics and Wellness · Sites in United States
Ages 18–75
Summit Hyperbarics and Wellness · Sites in United States
Ages 18–75
Summit Hyperbarics and Wellness · Sites in United States
Ages 18+
Neuroscience Group · Sites in United States
Ages 18+
Summit Hyperbarics and Wellness · Sites in United States
Ages 18–75
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 24 Post-Concussion Syndrome studies recruiting now, 3 (13%) set no upper age limit and 20 (83%) stop at 75 or younger; 2 take children under 18; 5 take healthy volunteers.
This study: 20 Years to 85 Years · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
77 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 8 · Phase 2 15 · Phase 3 2 · Phase 4 2
First in 2004; this study’s year is marked. 3 started in 2025.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 55 is close to the median of 52 across 113 interventional studies indexed under Post-Concussion Syndrome.
Median enrollment 40 across the 61 interventional studies, 90 across the 16 observational. Of the 51 that completed or were terminated, 13 (25%) have results posted.
This tab as a report to print or save as PDF → With an account.
3 of 77 have an industry lead sponsor. The 10 most frequent:
University of Wisconsin, Madison is the lead sponsor of 1,190 studies on the registry; 181 are open to participants now.
Of its 157 completed or terminated interventional studies of FDA-regulated products, 118 (75%) have results posted.
University of Wisconsin, Madison has 1 study filed under Post-Concussion Syndrome — fewer than ten, so there is no comparison to draw.
8 of the studies in Post-Concussion Syndrome with a site in United States that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT04978571Children's Hospital of Orange CountyPercutaneous Electrical Nerve Field Stimulation (PENFS) in Patients With Post Concussion Syndrome (PCS) | 2026-12 |
| NCT07303933Penn State UniversityFemale Concussion Head Cooling | 2027-01-01 |
| NCT07044596University of Wisconsin, MadisonNon-invasive Stimulation of the Glymphatic System for Slowing Cognitive Decline | 2027-06 |
| NCT07732374Summit Hyperbarics and WellnessLong-Term Outcomes Following HBOT | 2027-06-18 |
| NCT04760899University of IowaCerebellar TDCS for SRPCS Treatment | 2027-07 |
Add all 8 to your calendar (.ics) → With an account.
Among the 77 studies in Post-Concussion Syndrome with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The purpose of this research is to demonstrate that mild stimulation of a nerve (trigeminal nerve) in the head can modulate blood flow in the brain. The modulated blood flow will restore the flow of cerebrospinal fluid (CSF) and this in turn can help improve waste clearance in the brain and prevent build up that may lead to disease.
The goal of this clinical trial is to demonstrate that non-invasive stimulation of the trigeminal nerve can be used to restore blood flow and consequently modulate CSF flow into the brain parenchyma to facilitate brain waste clearance that is impaired in patients with AD. This study will collect brain MRI data on 20 healthy cognitively unimpaired adults receiving intermittent trigeminal nerve branch (V1) stimulation. Participants with recent mild traumatic brain injuries will also be enrolled to establish feasibility within a clinically relevant population.
140 studies on the registry are indexed under Post-Concussion Syndrome; 33 are open to participants now.
This study's planned enrollment of 55 is close to the median of 52 across 113 interventional studies indexed under Post-Concussion Syndrome.
Browse Post-Concussion Syndrome studies →University of Wisconsin, Madison is the lead sponsor of 1,190 studies on the registry; 181 are open to participants now.
Of its 157 completed or terminated interventional studies of FDA-regulated products, 118 (75%) have results posted.
Compared within Post-Concussion Syndrome, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Brain Concussion. The counts are of registry records indexed under each term, refreshed daily. How we classify →
Inclusion Criteria - Healthy Participants :
Inclusion Criteria - mTBI :
Exclusion Criteria - Healthy Participants:
Exclusion Criteria - mTBI:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Relapsed and refractory
Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Device: Functional near-infrared spectroscopy (fNIRS) · Device: V1 stimulation electrodes · Device: Magnetic Resonance Imaging (MRI) · Device: MAGNUS scanner
Participants with recent mTBI
Device: Functional near-infrared spectroscopy (fNIRS) · Device: V1 stimulation electrodes · Device: Magnetic Resonance Imaging (MRI)
fNIRS is a non-invasive imaging technique which takes advantage of the light scattering and absorption differences between oxygenated (HbO) and de-oxygenated hemoglobin (HbDO) to characterize changes in cerebral hemodynamics in response to a given task or stimulus.
The V1 electrodes will be placed on the forehead with some gel and held in place with a headband or cap (a conductive adhesive gel may be placed under the electrodes to help with stimulation). Participants will receive short electrical stimulations through these electrodes that will differ in intensity.
Participants will undergo 2 90-minute MRI sessions
Simultaneous Coherent-Incoherent Motion Imaging (SCIMI) available on the MAGNUS scanner will be used to perform quality control and optimization in healthy volunteers, to better resolve and visualize slow CSF flows within the brain.
Also known as: GE-MAGNUS 3T MRI scanner
Change in blood flow through the brain parenchyma - fNIRS
The fNIRS device will record changes in the blood oxygen level in the brain that is caused by the V1 stimulation.
Time frame: Baseline to 4 hours
Change in blood flow through the brain - MRI
The MRI will record changes in the blood oxygen level in the brain that is caused by the V1 stimulation.
Time frame: Baseline to 90 minutes
Change in cerebrospinal fluid flow
MRI scan will be used to measure the flow of cerebrospinal fluid before, during and after stimulation.
Time frame: Baseline to 90 minutes
Plan to share: No
No publications or documents are linked to this record.
Started Nov 2025 (actual). Primary completion is estimated for Jun 2027, 19 months after the start.
Of 54 non-industry interventional studies with no phase under Post-Concussion Syndrome, half reached primary completion within 40 months of starting (the median), counting those still running; a quarter within 24 and three quarters within 58. This study's planned 19 months is below that.
Counting every sponsor, half of 56 studies reached it within 40 months; a quarter within 23 and three quarters within 69.
Since we started tracking on Sep 25, 2026, the dates moved once, on Nov 4, 2026: primary completion Dec 2026 → Jun 2027 and completion Dec 2026 → Jun 2027.
Earlier changes are on the record history on ClinicalTrials.gov ↗
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
University of Wisconsin, Madison →